indication

Parkinson Disease

Competitive landscape projected to Melperone HCl’s launch window

as of 2026-07-01
Competitive set
4
3 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
38 events
2020
2024
2028
2032
2036
2040
2044
2048
today
Melperone HCl launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 32 trials
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Cannabidiol
Pipeline · Phase 2
Phase 22 trials
OwnerCentral Institute of Mental Health, Mannheim
Protection—

Market size

prevalence as a range, not a number